Unither Pharmaceuticals to acquire Carragelose portfolio from Marinomed Biotech

Marinomed Biotech AG signed an agreement to sell its Carragelose business to Unither Pharmaceuticals for up to EUR 20 million, including upfront and milestone payments, subject to regulatory and shareholder approvals.

“Unither Pharmaceuticals is a leading contract development and manufacturing organization of medical devices and pharmaceutical products with production sites in many parts of the world.”unither-pharma.com

• 1 source
• unither-pharma.comPress Release – Acquisition of the Carragelose Portfolio by Unither Pharmaceuticals | UnitheradminNov 19, 2024

Summarized from public sources; check the original articles before acting on it.